Is BME undervalued? Intrinsic value estimate stands at $1.3.
Get informed when a big investor buys or sells
+ Follow$1.29
Overvalued by 97.1% based on the discounted cash flow analysis.
BlackRock Health Sciences Trust's discounted cash flow stands at $1.3. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Discounted cash flow values BME by forecasting cash the business could generate and bringing those cash flows to present value. Stockcircle's latest estimate is $1.3, implying the shares look overvalued by about 97.1%. Pair DCF with P/E, growth, and balance-sheet metrics before making a decision.
The history chart shows how BlackRock Health Sciences Trust's DCF fair value evolved across reporting periods, while the comparison chart places BME next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.